{"id":"buparlisib-paclitaxel","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2364604","moleculeType":"Small molecule","molecularWeight":"446.86"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buparlisib is a pan-class I PI3K inhibitor that blocks phosphatidylinositol 3-kinase signaling, a pathway frequently dysregulated in cancer. Paclitaxel is a taxane that binds to β-tubulin and stabilizes microtubules, preventing mitotic spindle disassembly and inducing apoptosis. The combination exploits both growth signaling inhibition and direct cytotoxic mechanisms.","oneSentence":"Buparlisib inhibits PI3K signaling while paclitaxel stabilizes microtubules to prevent cell division, together targeting cancer cell proliferation through complementary pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:55:15.415Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer (phase 3 development)"}]},"trialDetails":[{"nctId":"NCT04338399","phase":"PHASE3","title":"The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC","status":"COMPLETED","sponsor":"Adlai Nortye Biopharma Co., Ltd.","startDate":"2020-12-12","conditions":"Head and Neck Cancer","enrollment":487},{"nctId":"NCT02117817","phase":"PHASE1","title":"Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer","status":"WITHDRAWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2015-02","conditions":"Ovarian Cancer, Endometrial Cancer, Recurrent Ovarian Cancer","enrollment":""},{"nctId":"NCT01285466","phase":"PHASE1","title":"A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Metastatic or Locally Advanced Solid Tumors","enrollment":110},{"nctId":"NCT01816594","phase":"PHASE2","title":"NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-03","conditions":"HER2-positive Newly Diagnosed, Primary Breast Cancer","enrollment":50},{"nctId":"NCT01820325","phase":"PHASE1","title":"Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-09","conditions":"Non-Small Cell Lunch Cancer","enrollment":6},{"nctId":"NCT01852292","phase":"PHASE2","title":"Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":157},{"nctId":"NCT01297452","phase":"PHASE1","title":"BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-02-15","conditions":"Solid Tumors","enrollment":45},{"nctId":"NCT01572727","phase":"PHASE2, PHASE3","title":"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Breast Cancer","enrollment":416},{"nctId":"NCT01953445","phase":"PHASE2","title":"Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2014-08","conditions":"Breast Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AN2025"],"phase":"phase_3","status":"active","brandName":"Buparlisib & Paclitaxel","genericName":"Buparlisib & Paclitaxel","companyName":"Adlai Nortye Biopharma Co., Ltd.","companyId":"adlai-nortye-biopharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buparlisib inhibits PI3K signaling while paclitaxel stabilizes microtubules to prevent cell division, together targeting cancer cell proliferation through complementary pathways. Used for Metastatic breast cancer (phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}